ADC Therapeutics SA 6-K, filed Jul 31, 2020

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORTOF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July, 2020.

Commission File Number: 001-39071

ADC Therapeutics SA

(Exact name of registrant as specifiedin its charter)

Biopôle

Routede la Corniche 3B

1066 Epalinges

Switzerland

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

On July 29, 2020, the board of directors of ADC Therapeutics SA (the “Company”) amended the Company’s organizational regulations to create the science and technology committee of the board of directors. The amendment is effective on July 29, 2020.

The science and technology committee, which consists of Victor Sandor (chair), Peter B. Corr, Peter Hug and Tyrell J. Rivers, is responsible for reviewing and making recommendations to the board of directors regarding the Company’s research and development activities, strategies, programs and objectives. The members of the science and technology committee and its chair are appointed by the Company’s board of directors. The science and technology committee has the responsibility to, among other things:

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.